Electromed (ELMD) Q2 2026 earnings summary

Executive summary

• Achieved record Q2 net revenues of $18.9 million, up 16.3% year-over-year, marking the 13th consecutive quarter of revenue and profit growth, driven by strong home care and distributor sales and increased awareness of bronchiectasis treatment options.

• Net income rose 40.3% to $2.8 million ($0.32 per diluted share), reflecting higher revenue and gross profit.

• Gross profit margin improved to 78.4% for the quarter, up from 77.7% in the prior year.

• Strategic focus on the underserved bronchiectasis market, with new marketing campaigns and expanded payer coverage.

• Strong operational execution and expanded sales force drove growth, especially in the core homecare market.

Financial highlights

• Net revenues for the quarter were $18.9 million (up from $16.3 million); six-month net revenues reached $35.8 million.

• Gross profit increased to $14.8 million (78.4% of net revenues), up from $12.6 million (77.7%).

• Operating income rose 42.4% to $3.6 million (19.2% of net revenues); net income up 40.3% to $2.8 million ($0.32 per diluted share).

• Cash on hand was $13.8 million with no debt; working capital of $36.2 million and shareholders' equity of $45.4 million.

• $3.8 million spent on share repurchases in the first half of fiscal 2026.

Outlook and guidance

• Management expects continued double-digit top-line growth and expanded operating leverage for the remainder of fiscal 2026.

• Plans to expand direct sales force to 61 representatives by year-end, with productivity expected to remain in the $1 million–$1.1 million per rep range.

• Ongoing investments in sales force and infrastructure are planned to support growth.